GALT: Meets FDA
Galectin Therapeutics announces positive Type C meeting with the FDA for Belapectin in patients with MASH cirrhosis and portal hypertension
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.